ArticleDiscover oncology2026
A clinically translatable pathomics-based predictive model for preoperative prognostic assessment in patients with endometrial cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial cancer (EC) is a common gynecologic malignancy with rising incidence and significant molecular heterogeneity. This study aimed to develop an integrated prognostic model using pathomics features derived from histopathological images.
methodsWe retrospectively analyzed hematoxylin and eosin-stained whole slide images and clinical data from 511 EC patients in the TCGA database. Pathomics features were extracted using the same methodology as the reference study. Patients were randomly divided into training (n = 341) and validation (n = 170) cohorts at a 2:1 ratio. Under a leave-one-out cross-validation framework, features were selected using LASSO combined with random survival forest to construct a pathomics score. Differential gene expression and functional enrichment were analyzed and a nomogram integrating the pathomics score with clinical variables was developed and evaluated.
resultsThe pathomics model demonstrated excellent prognostic prediction, with AUCs of 0.966, 0.724, and 0.918 in the training, validation, and whole cohorts for 5-year survival, respectively. The pathomics score showed significant associations with FIGO stage, grade, lymph node metastasis, and recurrence (p < 0.05). Differential gene expression analysis revealed enrichment in EC-related pathways, MAPK signaling, estrogen signaling, and HIF-1 signaling pathways. Multivariable analysis confirmed FIGO stage, grade, lymph node metastasis, and pathomics score as independent prognostic factors. The nomogram incorporating these factors showed significantly improved in overall survival (all p < 0.001 in the 3 cohorts) and predictive evaluation of AUCs (increases of 0.111, 0.132, and 0.118, respectively) with good calibration.
conclusionThe proposed nomogram integrating pathomics and clinical factors provides accurate prognostic prediction for EC patients, offering a valuable tool for risk stratification and personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.